Autolus Therapeutics (AUTL) Fundamental Analysis: Revenue, Earnings & Valuation

6.62 / 10

Outperform

Fundamentally the stock scores 6.6/10, rated Outperform. Asset‑MV and Revenue‑MV are undervalued, profit and cash modestly positive. Inventory turnover is decent, but current/fixed asset turnover, gross margin and cost‑of‑sales ratios are weak, limiting upside.

Analysis Checks(6/10)

Revenue-MV

Value-1.20

Score2/3

Weight23.16%

1M Return8.05%

Inventory turnover ratio

Value4.46

Score2/3

Weight-1.22%

1M Return-0.56%

Gross profit margin (%)

Value-39.02

Score1/3

Weight0.78%

1M Return0.36%

Profit-MV

Value0.41

Score2/3

Weight18.85%

1M Return6.36%

Income tax / Total profit (%)

Value-1.63

Score2/3

Weight2.37%

1M Return0.98%

Current assets turnover ratio

Value0.09

Score0/3

Weight-3.52%

1M Return-1.61%

Fixed assets turnover ratio

Value0.88

Score1/3

Weight-2.45%

1M Return-1.13%

Cost of sales ratio (%)

Value139.02

Score1/3

Weight-12.83%

1M Return-7.30%

Asset-MV

Value-0.48

Score3/3

Weight56.40%

1M Return15.70%

Cash-MV

Value-0.09

Score2/3

Weight18.47%

1M Return6.19%

Is AUTL undervalued or overvalued?

AUTL scores 6.62/10 on fundamentals and holds a Discounted valuation at present. Backed by its -56.93% ROE, -381.40% net margin, -1.12 P/E ratio, 1.21 P/B ratio, and -25.58% earnings growth, these metrics solidify its Outperform investment rating.